Quarterly ResultJul 29, 2026, 06:03 AM
Integra LifeSciences Q2 Revenue $418.8M; Adj. EPS $0.56
AI Summary
Integra LifeSciences reported Q2 2026 revenues of $418.8 million, a 0.8% increase, with adjusted diluted EPS rising 24.4% to $0.56. The company reaffirmed its full-year organic revenue growth and adjusted EPS guidance, while updating reported revenue guidance to reflect a stronger U.S. dollar. Operational progress includes initiating production at its Braintree facility and remaining on track for the SurgiMend® relaunch in Q4.
Key Highlights
- Q2 2026 revenues reached $418.8 million, up 0.8% reported and 0.7% organic.
- Adjusted diluted EPS increased 24.4% to $0.56 from $0.45 in prior year.
- GAAP diluted EPS was $0.06, significantly up from $(6.31) in Q2 2025.
- Full-year 2026 organic revenue growth guidance reaffirmed at 0.8% to 3.3%.
- Full-year 2026 adjusted EPS guidance reaffirmed at $2.40 to $2.50.
- Reported revenue guidance updated to $1.654 billion-$1.695 billion due to FX impact.
- Specialty Surgery segment revenue grew 1.7% reported to $309.3 million.
- Production initiated at Braintree facility; SurgiMend® relaunch on track for Q4.
Price Impact
More from IART